Abstract

OBJECTIVE

Stereotactic radiosurgery is an alternative treatment option in recurrent or residual pituitary adenomas. In this study, patients with pituitary adenoma who underwent stereotactic radiosurgery (SRS) with Cyberknife® were evaluated the response to treatment.

METHODS

Between January 2010- June 2013, 7 patients with pituitary adenomas underwent SRS in Ankara Oncology Hospital. Median age was 36 (range, 30-60) and 71% of cases (n=5) were male gender. All except one patient with hemophilia underwent surgery. Four cases with functioning adenomas were unresponsive to medical treatment and because of recurrent tumors, SRS was applied. Radiosurgery were performed in two cases due to residual tumor after surgery and one case due to medically inoperable. The median prescribed dose was 22 Gy (range, 20-25 Gy), in 3 and 5 fractions, with median 84% isodose line (range, 80%-93%).

RESULTS

The median follow-up time was 18 months (range, 14-55 months). A 55 months follow-up, one patient (non-functioning pituitary adenoma) showed clinical and radiological complete response. One patient with a functioning pituitary adenoma was progressing. In 6 of the seven patients (86%) tumor control were achieved.

CONCLUSION

Stereotactic radiosurgery is a safe and effective treatment option in the treatment of recurrent or residual pituitary adenomas.